Central Lab Market Share

North America Market Forecast

The North America region central lab market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The high prevalence of infectious and chronic diseases, an increase in patient awareness about the significance of laboratory tests, increasing adoption of technological developments with proper quality, efficient and effective serve, and a significantly growing proportion of research and development in the region. For instance, medical and health research and development (R&D) investment in the United States reached approximately USD 244 billion in 2020, an 11% expansion from 2019.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of central lab is assessed at USD 2.62 billion.

The central lab market size was valued at USD 2.49 billion in 2024 and is projected to reach USD 5.58 billion by the end of 2037, expanding at around 6.5% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of genetic disorders, rise in genetic testing, increasing prevalence of cancer, and growing investment in R & D will drive the market growth.

North America is anticipated to account for largest industry share by 2037, led by high prevalence of infectious and chronic diseases, an increase in patient awareness about the significance of laboratory tests, increasing adoption of technological developments with proper quality, efficient and effective serve, and a significantly growing proportion of research and development in the region.

The major players in the market include Laboratory Corporation of America Holdings (Labcorp), ICON Plc, Medpace, Inc., Eurofins Scientific (Ireland) Limited, LabConnect, Cerba Research NV, Frontage Laboratories, Inc., Lambda Therapeutic Research Limited, InVitro International (IVRO), Clinical Reference Laboratory, Inc.

Central Lab Market Share